{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:13Z","timestamp":1791402313755,"version":"4.3.3"},"reference-count":44,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Invasive fungal infections (IFIs) are a major complication in patients with acute myeloid leukemia (AML), particularly during chemotherapy-induced neutropenia. Posaconazole is the standard drug for primary antifungal prophylaxis (PAP), but its use is limited by oral bioavailability and CYP3A4 interactions. Study Objective: This study aims to evaluate the clinical efficacy and safety of intravenous caspofungin versus oral posaconazole as PAP in AML patients during their first cycle of chemotherapy and assess their subsequent impact on clinical outcomes. Methods: A retrospective, monocentric study was conducted on 75 consecutive AML patients treated at the Federico II University Medical School of Naples, Italy (2021\u20132025). Patients received either caspofungin or posaconazole as PAP based on the drug\u2013drug interaction risk or clinical conditions. IFIs were diagnosed using EORTC\/MSG criteria. Logistic and Cox regression models were used to assess risk factors and overall survival (OS). Results: IFI incidence was 13.3% overall (9.4% proven\/probable). No significant difference was found between the caspofungin and posaconazole groups (six vs. four IFIs; p = 0.878). Post-chemotherapy refractory AML (OR = 11.9; p = 0.003) and liver disease (OR = 30.4; p = 0.004) independently predicted IFI development. Median OS did not significantly differ in patients receiving caspofungin versus posaconazole (29.3 vs. 32.1 months, p = 0.6). Conclusions: Caspofungin appears clinically comparable to posaconazole for PAP in AML during the induction phase, especially when azole use is contraindicated. Prospective studies are warranted to refine prophylactic strategies in the era of new AML therapies.<\/jats:p>","DOI":"10.3390\/cancers17132184","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:18:36Z","timestamp":1751264316000},"page":"2184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-9406","authenticated-orcid":false,"given":"Francesco","family":"Grimaldi","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Memoli","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Avilia","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlangela","family":"Causa","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Giannattasio","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Conversano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Lisi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-0347","authenticated-orcid":false,"given":"Daniela","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Iannotta","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Schiano Moriello","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Infectious Diseases Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Viceconte","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Infectious Diseases Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Infectious Diseases Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-8451","authenticated-orcid":false,"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Infectious Diseases Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-4125","authenticated-orcid":false,"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/hematology.2020000098","article-title":"Updates in infection risk and management in acute leukemia","volume":"2020","author":"Logan","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2015-07-627323","article-title":"Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia","volume":"126","author":"Halpern","year":"2015","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofae082","DOI":"10.1093\/ofid\/ofae082","article-title":"Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies","volume":"11","author":"Young","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-019-03744-5","article-title":"Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: Impact of antifungal prophylaxis","volume":"98","author":"Montesinos","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dky550","article-title":"\u2018Real-life\u2019 analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study","volume":"74","author":"Dragonetti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_7","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QCO.0000000000000737","article-title":"Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients","volume":"34","author":"Coussement","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105886","DOI":"10.1016\/j.ijantimicag.2020.105886","article-title":"Itraconazole vs posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study","volume":"55","author":"Copley","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10238-023-01062-9","article-title":"The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: A systematic review and meta-analysis","volume":"23","author":"Soldi","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/11599810-000000000-00000","article-title":"Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: Review of the literature and options for clinical practice","volume":"72","author":"Tragiannidis","year":"2012","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14656566.2021.1996562","article-title":"Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections","volume":"23","author":"Panagopoulou","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Da Silva Ferreira, A.R., M\u00e4rtson, A.G., De Boer, A., Wardill, R.H., Alffenaar, J.W., Harmsen, H.J.M., and Tissing, W.J.E. (2021). Does chemotherapy-induced gastrointestinal mucositis affect the bioavailability and efficacy of anti-infective drugs?. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101389"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukemia treated with novel targeted therapies: A systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: Evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: The midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijantimicag.2011.07.008","article-title":"Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: A brief report","volume":"38","author":"Ngai","year":"2011","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/14787210.2020.1794817","article-title":"Caspofungin: A review of its characteristics, activity, and use in intensive care units","volume":"18","author":"Hashemian","year":"2020","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/jac\/dkr271","article-title":"A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)","volume":"66","author":"Cattaneo","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of randomized controlled trials","volume":"34","author":"Wang","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jpids\/piaa119","article-title":"A randomized trial of caspofungin vs. triazoles prophylaxis for invasive fungal disease in pediatric allogeneic hematopoietic cell transplant","volume":"10","author":"Dvorak","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: A randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: A randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"key":"ref_29","first-page":"267","article-title":"Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: A meta-analysis of randomized controlled trials","volume":"67","author":"Yuan","year":"2012","journal-title":"Pharmazie"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pagano, L., Maschmeyer, G., Lamoth, F., Blennow, O., Xhaard, A., Spadea, M., Busca, A., Cordonnier, C., Maertens, J., and ECIL (2025). Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia.","DOI":"10.1038\/s41375-025-02586-7"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Ratanatharathorn","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Alexander, B., Johnson, M., Bresnik, M., Anupindi, V., Pizzicato, L., DeKoven, M., Lovelace, B., and Coleman, C. (2024). Real-world antifungal therapy patterns across the continuum of care in United States adults with invasive aspergillosis. J. Fungi., 10.","DOI":"10.3390\/jof10120876"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1007\/s00520-016-3208-0","article-title":"Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: A retrospective study of the SEIFEM registry","volume":"24","author":"Picardi","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sharma, A., Mohamad, B., and Soubani, A.O. (2025). Epidemiology and inpatient outcomes of invasive aspergillosis in patients with liver failure and cirrhosis. J. Fungi, 11.","DOI":"10.3390\/jof11050334"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/myc.13524","article-title":"Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM\/Fungiscope","volume":"66","author":"Seidel","year":"2023","journal-title":"Mycoses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mold infection: An initiative of the European Confederation of Medical Mycology in cooperation with ISHAM and ASM","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.26846","article-title":"Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with venetoclax","volume":"98","author":"Candoni","year":"2023","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:00:44Z","timestamp":1760032844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":44,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132184"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132184","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]}}}